NCT01772732UnknownPhase 1
Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of Simotinib Hydrochloride in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Jiangsu Simcere Pharmaceutical Co., Ltd.1 site in 1 country30 target enrollmentStarted: December 2012Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Enrollment
- 30
- Locations
- 1
- Primary Endpoint
- Maximum tolerated dose (MTD)
Study Overview
Brief Summary
The primary objective is to assess the safety and tolerability of multiple doses of Simotinib Hydrochloride in NSCLC patients. The secondary objective is to determine the pharmacokinetic (PK) profile and explore the preliminary anti-tumor activity.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 65 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Patients with histologically or cytologically confirmed diagnosis of advanced NSCLC, who were previously treated with at least one platinum-based chemotherapy regimen, but had disease relapse;
- •Patients have ended their chemotherapy or radiotherapy at least 4 weeks prior to study entry and have recovered from any previous toxicity;
- •EGFR mutation positive (such as E19del、L858R、L861Q、G719X, etc.);
- •Patients with at least one measurable lesion meeting RECIST;
- •ECOG performance status 0-2;
- •Life expectancy ≥12 weeks;
- •Adequate bone marrow function: ANC ≥1.5 × 109/L, PLT≥80 ×109/L, HB ≥90 g/L;
- •Adequate hepatic function: serum bilirubin ≤ 2 × ULN, AST and ALT ≤ 2.5 × ULN, and ≤ 5 × ULN are acceptable if the liver has tumor involvement;
- •Adequate renal function: endogenous creatinine clearance rate (CrCl) ≥ 60 mL/min or serum creatinine ≤ 1.5 × ULN;
- •Females with childbearing potential must have a negative pregnancy test within 7 days prior to treatment and use an approved contraceptive method during the study;
- •Males must be surgically sterile or use an approved contraceptive method during the study.
Exclusion Criteria
- •Patients who were previously treated by EGFR inhibitor or other molecular targeting drugs (micromolecular drugs or monoclonal antibodies) such as Iressa, Tarceva, Sutent, Nexavar, Sprycel, Erbitux, Nimotuzumab, Icotinib, Herceptin, etc.;
- •The known hypersensitivity to Simotinib or any of the excipients;
- •Concurrent treatment with rifampin, rifabutin, rifapentine, dexamethasone, phenytoin sodium, carbamazepine, phenobarbital, Hypericum perforatum, atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, and telithromycin;
- •CNS metastasis diagnosed recently which has not received surgery or radiotherapy;
- •Evidence of interstitial lung disease;
- •Pre-existing idiopathic pulmonary fibrosis as evidenced by CT scan at baseline;
- •Any serious or uncontrollable systemic disease (such as unstable respiratory disorders, cardiovascular, hepatic or kidney disorders);
- •Any unstable systemic disorders (including active infection, uncontrollable hypertension, unstable angina pectoris, congestive heart failure, liver and kidney disorders or metabolism disease);
- •Other malignancies diagnosed within the last 5 years with the exception of completely cured cervical cancer in situ, or basal and squamous cell skin cancer;
- •Any remarkable eye disorders, especially severe dry eye syndrome, keratoconjunctivitis sicca, herpes keratitis;
- •History of nerve or psychiatric disorders, including epilepsy or dementia.
Arms & Interventions
Simotinib Treatment
Experimental
"3+3" design, ascending multiple doses. Simotinib Hydrochloride: 100mg, 200mg, 300mg, 400mg, 500mg, bid, for 28 days
Intervention: Simotinib Hydrochloride (Drug)
Outcomes
Primary Outcomes
Maximum tolerated dose (MTD)
Time Frame: 28 days
Secondary Outcomes
- The time to Cmax (tmax)(d1,d8,d9,d10,d15)
- Overall Response Rate (ORR)(1 year)
- The maximum plasma concentration (Cmax)(d1,d8,d9,d10,d15)
- Area under the plasma concentration-time curve (AUC)(d1,d8,d9,d10,d15)
- Progression-free Survival (PFS)(1 year)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 1
Staccato Loxapine Multidose PKVolunteers on Chronic, Stable Antipsychotic RegimensNCT00555412Alexza Pharmaceuticals, Inc.40
Completed
Phase 1
Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of BI 113608 in Healthy Male VolunteersHealthyNCT01681277Boehringer Ingelheim48
Completed
Phase 1
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising DosesHealthyNCT01505894Boehringer Ingelheim83
Completed
Phase 1
Safety, Tolerability, and Pharmacokinetics of Multiple Rising Doses of BI 425809 Tablets for 12 Days to Young and Elderly Healthy Male and Female Volunteers and Comparison of Pharmacokinetics of a Single Oral Dose of BI 425809 (Morning Versus Evening)HealthyNCT02337283Boehringer Ingelheim96
Completed
Phase 1
A Study to Test How Well Different Doses of BI 1815368 Are Tolerated by Healthy MenHealthyNCT05857878Boehringer Ingelheim59